In the last decade, there have been a number of groundbreaking new therapies to treat MS, and Novartis is at the forefront of some of these innovations, for example:
- making the first oral disease-modifying therapy (DMT) available for adults with relapsing MS in 2011
- offering the first and only oral medicine approved for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS) in 2018
- introducing the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease, a debilitating form of MS with limited treatment options, in 2019
- making the first and only self-administered, targeted B-cell therapy available for a broad range of RMS patients that can be self-administered at home in 2020
Novartis is dedicated to providing MS patients with therapeutic solutions based on the latest science, and will continue to push the boundaries by leading on new ways to assess disease activity, conduct research and measure outcomes for people living with MS worldwide.